takeda investor presentation 2020

These non-IFRS measures exclude certain income, cost and cash flow items which are included in, or are calculated differently from, the most closely comparable measures presented in accordance with IFRS. Pork prices declined 14.9% in February from a year ago, reflecting the recovery in hog supplies after outbreaks of African swine fever in recent years.That trend could reverse with the re-emergence of the disease in parts of the country. During FY2019, Takeda completed the purchase price allocation for the assets acquired and the liabilities assumed as part of the Shire acquisition. This honor demonstrates Takeda’s continued commitment to creating an exceptional people experience for its global workforce. Lazada CEO Shares Key for E-commerce Success in Southeast Asia (December 2, 2020) Highlights of the 2020 11.11 Global Shopping Festival (November 12, 2020… These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. This honor demonstrates Takeda’s continued commitment to creating an exceptional people experience for its global workforce. GastroenterologyThe Gastroenterology franchise with JPY 588.8 billion in reported revenue represented 24% of sales, with underlying revenue growth of 14%. Additionally, Takeda plans to acquire all the shares of Amgen's Japanese subsidiary, Amgen KK. The revenue of Shire plc ("Shire"), which was historically, presented by Shire in accordance with accounting principles generally accepted in the United States ("U.S. GAAP"), has been conformed to IFRS, without material difference. COST SAVINGS AND DIVESTITURESSynergy deliverables and operational efficiencies supported margin performance, as Takeda delivered a year-to-date underlying core operating profit margin of 32.1%. The company also operates Covid-19 mobile testing and vaccination units through an arm known as Rapid Reliable Testing, which has handled about 1.2 million tests and administered about 25,000 vaccines.The company, which has partnerships with dialysis specialist Fresenius Medical Care, New Jersey hospital network Jefferson Health and Colorado’s UCHealth, also provides on-site medical services at events. Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2020 Financial Results, and Host Conference Call on February 10, 2021. Media outside Japan Chris Stamm chris.stamm@takeda.com +1 (617) 347-7726. (Bloomberg) -- Ambulnz Inc., a provider of mobile medical services and patient transportation, has agreed to go public through a merger with Motion Acquisition Corp.The special purpose acquisition company is raising $125 million in new equity from investors including Light Street Capital and Moore Strategic Ventures to support the transaction, which is set to value the combined entity at about $1.1 billion, according to a statement Tuesday, following an earlier Bloomberg report.Ambulnz, to be renamed DocGo Inc., is led by Chief Executive Officer Stan Vashovsky. Underlying core operating profit grew 8.5% year-on-year. This trend has fluctuated throughout the nine-month period, especially in recent months, as transmission of COVID-19 has increased significantly in many parts of the world. Hemophilia Spin-off Presentation. Further InformationTakeda will share details regarding its commercial strategy in emerging markets and progress on its pipeline at its upcoming Growth & Emerging Markets Strategic Update call on March 11, 2021 and part 2 of its Wave 1 Pipeline Market Opportunity call on April 6, 2021, respectively. 12, 2020 Takeda Pharmaceutical Company Limited (TKPHF) on Q4 2019 Results - Earnings Call Transcript Rare Hematology declined 11% on an underlying basis, with the competitive landscape in line with expectations. (Press Release)KEY CORPORATE INITIATIVESSeveral examples of corporate achievements in Q3 demonstrate Takeda’s progress toward its vision — “discover and deliver life-transforming treatments, guided by our commitment to Patients, our People and the Planet.”Patients:Takeda Demonstrates Industry Leadership in 2021 Access to Medicines IndexTakeda was ranked sixth overall in the 2021 Access to Medicine (AtM) Index. Yet the gauge renewed its decline in the afternoon to close down 2.2% at its lowest level since December, a move that stood out against an upbeat day in global shares. Thank you. A picture of an ice cream cone tweeted by Cohen on Feb. 25 helped spark a massive rally, with the stock doubling at one point during the session.Monday’s rally came despite short interest being near the lowest level in at least a year. A rigorous, biennial research project, the AtM Index combines data-collection, verification, scoring and analysis to compare 20 of the world’s largest pharmaceutical companies on their efforts to address access to medicines. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). (, The completion of the previously announced sale of TachoSil, The completion of the previously announced sale of a portfolio of select prescription products to Cheplapharm for a total value of $562 million USD. i Please note the December 2020 debt profile assumes completion of ongoing make-whole calls on $1.25B 2021, $0.9B 2021 and $0.3B 2022 (completion scheduled for FY2020 Q4). ", Patients:Takeda Demonstrates Industry Leadership in 2021 Access to Medicines IndexTakeda was ranked sixth overall in the 2021 Access to Medicine (AtM) Index. Takeda further exceeded its original $700 million target and Q2 total of $1.1B for incremental cash from sales of real estate and securities, receiving ~$1.4B to date. Consumer prices fell 0.2% last month from a year earlier, slightly better than a projected 0.3% decline.As manufacturer to the world, resurgent producer prices in China raise the prospect it will start exporting inflation globally as factories hike prices for goods sold abroad. Takeda has solid growth momentum heading into Q4 FY2020 and potential for accelerated underlying growth and achieving an underlying core operating profit margin in the mid-30s over the medium term.Core and underlying guidance for FY2020 remains unchanged. For Investors & Analysts Earnings Release Presentation Committed to Bringing Better Health and a Brighter Future to People Worldwide Click to download Christophe Weber, President & Chief Executive Officer Andrew Plump, President, Research & Development Costa … Other Notable UpdatesIn 2020, Takeda ranked first in NDA approvals in China, with four approvals including TAKHZYRO (Press Release), ENTYVIO, ADCETRIS, and REPLAGAL. Takeda is committed to addressing the world’s biggest challenges to sustainable development over the long term. Free cash flow, which also reflects capital expenditures and proceeds from asset sales, was JPY 717.5 billion (~$7.0B). Already gaining traction before the pandemic, the category got a major boost in the supermarket aisles during 2020 as consumers, sometimes unable to find their favorite cuts of meat, increasingly cooked at home.Beyond shares climbed 4.4% at 9:36 a.m. in New York.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P. Tesla was short-sellers' biggest win, giving them estimated profits of $4.2 billion so far in 2021, followed by more than $1 billion gains each on Zoom Video and Apple, according to Ortex. It posted revenue of about $94 million in 2020, nearly double the year-earlier amount. The answer may very well be yes, but with a nuance: Some experts think there are a series of microbubbles gurgling up rather than a single immense boom. The yuan swung between gains and losses amid the ructions in the stock market before rising 0.2% against the greenback as of 6 p.m. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. BOTHELL, Wash.--(BUSINESS WIRE)-- Seagen Inc. (Nasdaq:SGEN) today announced multiple ADCETRIS ® (brentuximab vedotin) data presentations at the 62 nd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place virtually December 5-8, 2020. (Press release). The U.K.’s Cairn, together with Cairo-based Cheiron Petroleum Corp., will buy the assets for $646 million and make additional payments of as much as $280 million by 2024, “contingent on the oil price and the results of further exploration,” Shell said in a statement.The deal “will enable Shell to concentrate on its offshore exploration and integrated value chain in Egypt, including seven new blocks in the Nile Delta, West Mediterranean and Red Sea,” the Anglo-Dutch oil major said.Cairn, in turn, is selling its stakes in the U.K.’s Catcher and Kraken fields to Waldorf Production U.K. Ltd. for $460 million with a further uncapped contingent consideration dependent on oil-price and production performance. The company, which already sells some products at 2,400 of the retailer’s locations, will also expand its cookout-themed value pack to 500 of the stores.The expansion of the partnership that began in 2015 underscores the increasing demand for plant-based food, which is showing up in grocery stores and on restaurant menus worldwide. Takeda excelled globally in the areas of Values, Ethics & Integrity, Organizational Change, Leadership, Sustainability, Performance Management and Engagement and was also certified as a Top Employer in four regions and 38 countries. He said he didn’t “see anything new there at all.”Instead, the stock’s position as a “Reddit Raider favorite” likely spurred the rally, according to Pachter. The Communist Party, which has long sought to cultivate a ‘slow’ bull market in equities, will need to do more to restore sentiment this time.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P. (Bloomberg) -- Saudi Arabia’s push to restrain oil supply to buoy prices is spurring India to speed up plans to diversify its crude sources and pursue alternative energy, the chairman of one of the nation’s biggest refiners said.The world’s third-biggest oil importer was already trying to cut its dependence on Middle Eastern crude, with American oil rising from 0.5% of total purchases to 6% over the past five years, Mukesh Kumar Surana, chairman of state-owned Hindustan Petroleum Corp., said in a Bloomberg Television interview.Indian Oil Minister Dharmendra Pradhan has repeatedly called for OPEC+ to pump more crude to stop prices from rising too high. (Bloomberg) -- Beyond Meat Inc.’s shares jumped after the faux-meat maker said it would broaden its product offerings at Walmart Inc.The maker of plant-based burgers will begin selling a meatless hot Italian sausage at 400 Walmart locations across the U.S. this week, Beyond said Tuesday in a statement. Investor Relations: Christopher O’Reilly takeda.ir.contact@takeda.com +81 (0) 3-3278-2306 Media outside Japan Justine Grosvenor justine.grosvenor@takeda.com +1 872 226 … Lavina Talukdar-- Head of ... We have partnered with Medison in Israel and with Takeda … The decision and an attack on an export terminal in the kingdom pushed Brent above $71 a barrel on Monday.“Higher prices make the future of oil as a commodity in the energy basket more detrimental,” Surana said. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Home; Investors; Financial results and events; Investor presentations ; Investor presentations . With regard to operating expenses, voluntary suspension of certain business activities such as business travel and events in response to COVID-19 led to lower spending. By including these non-IFRS measures, management intends to provide investors with additional information to further analyze Takeda’s performance, core results and underlying trends. Global bonds have gained 382% since 1991, or about 5.4% a year, based on the Bloomberg Barclays Global Aggregate Index.“We’re repeating the same message that going forward the returns are going to be much harder,” said Brake, whose fund has returned 9.2% a year over the past decade. (3) Core Operating Profit represents net profit adjusted to exclude income tax expenses, the share of profit or loss of investments accounted for using the equity method, finance expenses and income, other operating expenses and income, amortization and impairment losses on acquired intangible assets and other items unrelated to Takeda’s core operations, such as purchase accounting effects and transaction related costs. (, The completion of the previously announced sale of a portfolio of select products to Celltrion Inc. for a total value of $278 million USD inclusive of milestone payments. Takeda will also pay to Amgen up to $340 million in expected worldwide development costs for these molecules over the next several years, $362 million in success-based milestone payments, and double digit royalties on sales in Japan. Officials repeatedly warned of asset bubbles and said that curbing risks in the financial system was this year’s key policy goal. This would support increases in profits for industrial enterprises -- a positive for the economy.-- David Qu, China economistFor the full report, click here.However, the government’s conservative economic growth goal of more than 6% for this year, and its gradual withdrawal of stimulus mean China could play a lesser role in driving demand for commodities this year than in the years following the global financial crisis.“China may play a less dominant role in exporting global inflation, given that the government’s on the course to tighten fiscal stimulus and property measures,” said Michelle Lam, Greater China economist at Societe Generale SA in Hong Kong. Minimizing the environmental impact of its business is a critical priority for Takeda and at the heart of its purpose: achieving Better Health for People, Brighter Future for the World. Evidence of intervention includes buying through trading links with Hong Kong.Authorities had in many ways encouraged the recent correction in stocks after the CSI 300 briefly surpassed its closing record last month. Takeda’s pipeline portfolio has the potential to contribute significantly to its growth over the next decade, and remains on track to deliver on its milestone goals. Other Officials repeatedly warned of asset bubbles and said that curbing risks in the financial system was this year’s key policy goal. There was no significant impact on China’s local credit market, traders said.The China Securities Regulatory Commission didn’t immediately reply to a fax seeking comment on whether state funds were behind Tuesday’s moves. About Takeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company Limited (TOKYO: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. The portfolio experienced a slowdown in momentum attributable to COVID-19 stay-at-home restrictions that reduced patient visits and diagnoses. Cambridge, MASS. The company achieved notable high scores in all three technical areas evaluated by the Index, including being ranked first in "Governance of Access". Oil has surged close to $70 a barrel, while prices of copper and agricultural goods have rallied. That compares to a peak of more than 140% in January.“Shorts will continue to be squeezed out of their positions as GameStop’s stock price continues to trend upwards,” said Ihor Dusaniwsky, managing director of predictive analytics at S3 Partners.Shorts sellers are down nearly $6 billion in year-to-date mark-to-market losses, including $609 million in Monday’s trading alone, Dusaniwsky said by email.GameStop’s market value jumped to $13.6 billion as retail investors praised Cohen’s move on social media sites like Twitter and Reddit. Facebook; Twitter; LinkedIn; 2021. Takeda Pharmaceutical … Takeda Pharmaceutical Company Limited 2020 Q4 - Results - Earnings Call Presentation (NYSE:TAK) - Flipboard Full Year 2020 Financial Results Total revenues for 2020 were $186.4 million, compared with $120.3 million for 2019. The overall impact of the global spread of COVID-19 on Takeda’s consolidated financial results for the nine-month period ended December 31, 2020 was not material, with several offsetting factors. Please read our privacy notice for more information on the cookies we use, the processing of your personal data and how to delete or block the use of cookies. (Press Release), The completion of the previously announced sale of a portfolio of select prescription products to Cheplapharm for a total value of $562 million USD. By including these non-IFRS measures, management intends to provide investors with additional information to further analyze Takeda’s performance, core results and underlying trends. PDT ImmunologyPDT Immunology with JPY 313.0 billion in reported revenue represented 13% of sales, with underlying revenue growth of 9% driven by continued strong Gammagard-Liquid demand in the U.S. and subcutaneous IG worldwide. CAMBRIDGE, Mass. The Nasdaq posted its biggest single-day rise since Nov. 4. 3 February 2021 - FY 2020 results: EN: 28 October 2020 - Q3 2020 results: EN: 29 July 2020 - Q2 2020 results: EN: 29 April 2020 - Q1 2020 results: EN: 5 February 2020 - FY 2019 results: EN: 23 October 2019 - Q3 2019 results: EN: 31 July 2019 - Q2 2019 results: EN: 23 April 2019 - Q1 2019 results: EN: 6 February 2019 - FY 2018 results: EN That figure is expected to surpass $155 million this year.Motion Acquisition, led by CEO Michael Burdiek, raised $115 million in an October initial public offering and said at the time it would focus on searching for target businesses in connected vehicle industries globally.While there are other companies focused on telehealth, such as Teladoc Health Inc. and American Well Corp,. Dec. 11, 2020 Country Risk Exposure (As of the end of September 2020) Oct. 21, 2020 As a values-based and R&D driven biopharmaceutical company, we remain focused on bringing life-transforming treatments to people with high unmet needs around the world. “You can’t hide in the corner and not invest any more because we have to get our returns and I don’t think it’s the kind of environment where we should be doing that.”Norway’s $1.3 trillion sovereign wealth fund has already made the shift, winning approval to adjust its equity-bond mix to 70/30 in 2017. Large insurers in Beijing and Shanghai bought stocks on Tuesday as the market tumbled, according to a Shanghai Securities News report.To be sure, authorities had in some ways encouraged the recent correction. Positive Phase 3 data for TAK-620 will be presented at the Transplantation & Cellular Therapy Meetings (TCT) on February 12 and the European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting on March 14-17. Ovid Investors and Media: Ovid Therapeutics Inc. Investor Relations & Public Relations irpr@ovidrx.com. Mobocertinib (TAK-788), a potential new oral standard of care for NSCLC patients with EGFR Exon20 insertion mutations, demonstrated clinically meaningful and durable responses in data presented at the 2020 World Conference on Lung Cancer (WCLC), with a confirmed objective response rate of 35% as assessed by investigator and a median duration of response of 17.5 months. As a result, the Company is raising its full year FY2020 Free Cash Flow forecast by JPY 50 billion to JPY 750 – 850 billion. With regard to operating expenses, voluntary suspension of certain business activities such as business travel and events in response to COVID-19 led to lower spending. Any failure to comply with these restrictions may constitute a violation of applicable securities laws.The companies in which Takeda directly and indirectly owns investments are separate entities. Investor presentations. Under a suite of new EU finance rules due to be rolled out in stages, beginning on March 10, firms including fund houses, insurers and pension funds that provide financial products or services in the European Union will have to begin disclosing how sustainable they really are. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. (Updates throughout, adding comments from economists. Robust cash flow enabled further de-leveraging in Q3 and led to a 3.6x net debt/adjusted EBITDA ratio at the end of the period. COMMERCIAL UPDATES ACROSS FIVE KEY BUSINESS AREASTakeda’s five key business areas — Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology and Neuroscience — with JPY 1,982.1 billion of reported revenue representing approximately 82% of total Q3 YTD revenues – delivered year-on-year underlying revenue growth of 4.4%. These adverse impacts have been partially offset by benefits from prescribing trends during the pandemic, such as an expansion of certain products with a more convenient administration profile that was observed in the early phase of the outbreak. This progress reflects our ability to effectively and efficiently integrate the operations of Takeda and Shire, as we capture synergies and focus investment in our key business areas. )For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P. (Bloomberg) -- Cairn Energy Plc reshuffled its portfolio, selling $460 million of assets in the U.K. North Sea and buying projects in Egypt’s Western Desert from Royal Dutch Shell Plc.Both deals, announced Tuesday and seen completing in the second half of 2021, follow a pickup in oil and gas acquisitions after 2020’s pandemic-driven slump. Convenience translations of JPY figures into USD are included for reference and have been calculated at a rate of JPY/USD of 103.19. 2020-08-17 MMMM D, YYYY. (Press Release)At the 2020 American College of Allergy, Asthma and Immunology (ACAAI) Virtual Annual Scientific Meeting, Takeda shared final results from the Phase 3 HELP Study™ Open-Label Extension that demonstrate TAKHZYRO (lanadelumab-flyo) injection as a potential long-term preventive treatment option in patients with Hereditary Angioedema. Takeda has also undertaken a number of efforts to help the world respond to COVID-19, most recently including: World’s Leading Life Science Companies Now Enrolling COMMUNITY, A Global Platform Trial For Hospitalized Patients with COVID-19, Takeda initiates a clinical phase 1/2 study in Japan of TAK-919, Moderna’s COVID-19 vaccine candidate, Takeda licensed TAK-919 (Moderna) and TAK-019 (Novavax) COVID-19 vaccines in Japan, with approvals expected in FY2021, FY2020 GUIDANCEFull-Year Management Guidance Confirmed; Reported EPS Upgrade on More Favorable Tax Rate Assumption and Increased Forecast for Free Cash Flow Reflecting Additional Sale of Securities. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Underlying core operating profit margin, which adjusts for the impact of foreign exchange and divestiture effects, was 32.1%, driven by synergies and OPEX efficiencies.Takeda’s reported net profit was JPY 178.9 billion, a 320.8% increase compared with the same period in the prior year.Operating cash flow increased by 25.9% to JPY 610.0 billion, strengthening Takeda’s balance sheet and more than enabling the Company to satisfy dividend, debt, and interest payments. Takeda also demonstrated strong performance in the areas of health strengthening and compliance. The overall impact of the global spread of COVID-19 on Takeda’s consolidated financial results for the nine-month period ended December 31, 2020 was not material, with several offsetting factors. Takeda’s management evaluates results and makes operating and investment decisions using both IFRS and non-IFRS measures included in this press release. In this press release, "Takeda" is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Takeda is also deleveraging rapidly, with a net debt/adjusted EBITDA ratio of 3.6x at the end of Q3 (December 31, 2020), down from 3.8x in March 2020, even after the full-year dividend payment. Takeda’s management evaluates results and makes operating and investment decisions using both IFRS and non-IFRS measures included in this press release. )For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P. https://www.takeda.com/investors/reports/quarterly-announcements/, https://www.takeda.com/corporate-responsibility/sustainable-value-report/, https://www.takeda.com/investors/reports/sec-filings/, https://www.businesswire.com/news/home/20210203006048/en/, Stock market news live updates: Stock futures mixed after rally, Treasury yields climb, GE Sells Jet Lessor to AerCap in $30 Billion Deal to Cut Risk, U.K. Lashes Out at EU; New Data on Lilly Antibody: Virus Update, World is missing chance for green recovery from COVID-19, U.N. says, Citi Blocks Firms With Errant Revlon Payout From Debt Deals, 5 tax changes that can take you by surprise this filing season, U.S. Dollar Index (DX) Futures Technical Analysis – Close Under 92.33 Forms Bearish Closing Price Reversal Top, Short-sellers made billions from U.S. tech selloff, GameStop inflicts losses - Ortex, S&P 500 Price Forecast – Stock Markets Celebrate Falling Yields, Beyond Meat Shares Jump on Expanded Partnership With Walmart, Gold Price Futures (GC) Technical Analysis – Strong Move Through $1711.70 Could Trigger Surge into $1744.30, Ambulnz Agrees to Go Public Via Motion Acquisition SPAC, Death of 60/40 Portfolio Makes Returns Harder for Funds, EUR/USD Mid-Session Technical Analysis for March 9, 2021, SoftBank Poised to Reap $16 Billion Profit as Coupang Boosts IPO, China Producer Prices Jump, Adding to Global Inflation Risks, Shell Strikes $926 Million Deal to Sell Oil Assets in Egyptian Desert, ‘Reddit Raider’ Favorite GameStop Soars on Latest Cohen Push, Flutterwave has raised $170 million with a bid to connect Africa’s digital payment landscape, EU prepares to turn the screw on asset managers over greenwashing, China State Funds Buy Stocks to Stem Worsening Rout, Saudi Oil Hawkishness Speeds India Plan to Seek Alternatives, China’s $1.3 Trillion Stock Rout Tests Limit of Intervention.

What Channels Come With Frontier, Hse Medical Officer, Walsall Vs Carlisle Prediction, Lego Batman 1966 Minifigures, Summer Camp Near Me Jobs, Ucc Online Communion, Dublin Evening Herald Archives, World Map Hd Wallpaper 4k, French-canadian Christmas Eve Meal, Rosemary Leaves Meaning In Urdu, Smokey Joe Williams Baseball Reference,